{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477241639
| IUPAC_name = 2-Amino-''N'',''N''&prime;- bis[(6''S'',9''R'',10''S'',13''R'',18a''S'')-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxohexadecahydro-1''H''-pyrrolo[2,1-''i''][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-3''H''-phenoxazine-1,9-dicarboxamide
| image=Actinomycin D.png
| width=
| image2=Actinomycin D sticks.png
<!--Clinical data-->
| tradename = Cosmegen
| Drugs.com = {{drugs.com|monograph|dactinomycin}}
| MedlinePlus = a682224
| pregnancy_AU = D
| pregnancy_US = D
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = [[Intravenous therapy|IV]]
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 5%
| metabolism =  
| elimination_half-life = 36 hours
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50-76-0
| ATC_prefix = L01
| ATC_suffix = DA01
| ATC_supplemental =  
| PubChem = 2019
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00970
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10482167
| NIAID_ChemDB = 009885
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1CC1JFE158
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = C06770
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 27666
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1554
<!--Chemical data-->
| C=62 | H=86 | N=12 | O=16
| molecular_weight = 1255.42 g/mol
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RJURFGZVJUQBHK-IIXSONLDSA-N
| synonyms = Actinomycin D<br/><small>2-Amino- 4,6-dimethyl- 3-oxo- 3H-phenoxazine- 1,9-dicarboxylic acid bis- [(5,12-diisopropyl- 9,13,16-trimethyl- 4,7,11,14,17-pentaoxo- hexadecahydro- 10-oxa- 3a,6,13,16-tetraaza- cyclopentacyclohexadecen- 8-yl)- amide]</small>
}}
<!-- Definition and medical uses -->
'''Dactinomycin''', also known as '''actinomycin D''', is a [[chemotherapy medication]] used to treat a number of types of [[cancer]].<ref name=AHFS2016/> This includes [[Wilms tumor]], [[rhabdomyosarcoma]], [[Ewing's sarcoma]], [[trophoblastic neoplasm]], [[testicular cancer]], and certain types of [[ovarian cancer]].<ref name=AHFS2016/> It is given by [[intravenous|injection into a vein]].<ref name=AHFS2016/>

<!-- Side effects and mechanism -->
Most people develop side effects.<ref name=AHFS2016/> Common side effects include [[bone marrow suppression]], vomiting, mouth ulcers, hair loss, [[liver problems]], infections, and muscle pains.<ref name=AHFS2016/> Other serious side effects include future cancers, [[allergic reactions]], and [[necrosis|tissue death]] at the site of injection.<ref name=AHFS2016/> Use in [[pregnancy]] may harm the baby.<ref name=AHFS2016/> Dactinomycin is in the [[cytotoxic antibiotic]] family of medications.<ref name=BNF69>{{cite book|title=British national formulary : BNF 69|date=2015|publisher=British Medical Association|isbn=9780857111562|page=582|edition=69}}</ref> It is believed to work by blocking the creation of [[RNA]].<ref name=AHFS2016/>

<!-- History and culture -->
Dactinomycin was approved for medical use in the United States in 1964.<ref name=AHFS2016>{{cite web|title=Dactinomycin|url=https://www.drugs.com/monograph/dactinomycin.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20131609200900/http://www.drugs.com/monograph/dactinomycin.html|archivedate=11 September 2017|df=}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> The wholesale cost in the [[developing world]] is about 24.73 USD per 500 mcg vial.<ref name=ERC2014>{{cite web|title=Dactinomycin|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=DAC500I&s_year=2014&year=2014&str=500%20mcg&desc=Dactinomycin&pack=new&frm=VIAL&rte=INJ&class_code2=08%2E2%2E&supplement=&class_name=%2808%2E2%2E%29Cytotoxic%20and%20adjuvant%20medicines%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}</ref> It is produced from [[bacteria]] ''[[Streptomyces parvullus]]''.<ref name=AHFS2016/>

== Medical use ==
Actinomycin is a clear, yellow liquid administered intravenously and most commonly used in treatment of a variety of cancers, including:
*[[Gestational trophoblastic neoplasia]]<ref>{{cite journal |author=Turan T |author2=Karacay O |author3=Tulunay G |author4= Boran N |author5=Koc S |author6= Bozok S |author7=Kose M |title=Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia |journal=Int J Gynecol Cancer |volume=16 |issue=3 |pages=1432–8 |year= 2006|pmid=16803542 |doi=10.1111/j.1525-1438.2006.00606.x}}</ref>
*[[Wilms' tumor]]<ref>{{cite journal |author=D'Angio GJ |author2= Evans A |author3=Breslow N |author4=Beckwith B |author5=Bishop H |author6=Farewell V |author7=Goodwin W |author8= Leape L |author9=Palmer N |author10= Sinks L |author11=Sutow W |author12= Tefft M |author13=Wolff J |title=The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. |journal=Cancer | volume=47 |issue=9 |pages=2302–11 |year=1981 |pmid= 6164480 |doi=10.1002/1097-0142(19810501)47:9<2302::aid-cncr2820470933>3.0.co;2-k}}</ref>
*[[Rhabdomyosarcoma]]<ref>{{cite journal |author=Khatua S |author2=Nair C |author3=Ghosh K |title=Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues |journal=J Pediatr Hematol Oncol |volume=26 |issue=11 |pages=777–9 |year=2004 |pmid=15543019 |doi=10.1097/00043426-200411000-00020}}</ref>
*[[Ewing's sarcoma]]<ref>{{Cite journal| doi = 10.1002/1097-0142(197611)38:5<1925::AID-CNCR2820380510>3.0.CO;2-J| last1 = Jaffe | first1 = N.| last2 = Paed | first2 = D.| last3 = Traggis | first3 = D.| last4 = Salian | first4 = S.| last5 = Cassady | first5 = J. R.| title = Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy| journal = Cancer| volume = 38| issue = 5| pages = 1925–1930| year = 1976| pmid = 991106}}</ref>
*Malignant [[hydatidiform mole]]<ref>{{Cite journal| last1 = Uberti | first1 = E. M. H.| last2 = Fajardo | first2 = M. D. C.| last3 = Ferreira | first3 = S. V. V. R.| last4 = Pereira | first4 = M. C. V.| last5 = Seger | first5 = R. C.| last6 = Moreira | first6 = M. A. L. R.| last7 = Torres | first7 = M. D.| last8 = De Nápoli | first8 = G.| last9 = Schmid | first9 = H.| doi = 10.1016/j.ygyno.2009.09.012| title = Reproductive outcome after discharge of patients with high-risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy| journal = Gynecologic Oncology| volume = 115| issue = 3| pages = 476–481| year = 2009| pmid = 19818481| pmc = }}</ref>
Sometimes it will be combined with other drugs in [[chemotherapy regimens]], like the VAC regimen (with [[vincristine]] and [[cyclophosphamide]]) for treating rhabdomyosarcoma and Ewing's sarcoma.

It is also used as a [[radiosensitizer]] in adjunct to [[radiotherapy|radiotherapies]], since it can increase the [[radiosensitivity]] of [[Neoplasm|tumor cells]] by inhibiting repair of sublethal radiation damage and delay the onset of the compensatory hyperplasia that occurs following irradiation.<ref>{{Cite journal| last1 = Hagemann | first1 = R. F.| last2 = Concannon | first2 = J. P.| doi = 10.1259/0007-1285-46-544-302| title = Mechanism of intestinal radiosensitization by actinomycin D| journal = British Journal of Radiology| volume = 46| issue = 544| pages = 302–308| year = 1973| pmid =  4720744| pmc = }}</ref>

== Side effects ==
Common [[adverse drug reaction]] includes [[bone marrow suppression]], [[Fatigue (medical)|fatigue]], [[hair loss]], [[mouth ulcer]], [[loss of appetite]] and [[diarrhea]]. Actinomycin is a [[vesicant]], if extravasation occurs.

==Mechanism==
In [[cell biology]], actinomycin D is shown to have the ability to inhibit [[Transcription (genetics)|transcription]]. Actinomycin D does this by binding [[DNA]] at the transcription initiation complex and preventing elongation of [[RNA]] chain by [[RNA polymerase]].<ref>{{cite journal |author=Sobell H |title=Actinomycin and DNA transcription |journal=Proceedings of the National Academy of Sciences of the United States of America |volume=82 |issue=16 |pages=5328–31 |year=1985 |pmid=2410919 |doi=10.1073/pnas.82.16.5328 |pmc=390561}}</ref>

== History ==
Actinomycin D was the first [[antibiotic]] shown to have anti-[[cancer]] activity.<ref name="gen">{{cite journal|last1=Hollstein|first1=U.|title=Actinomycin. Chemistry and mechanism of action|doi=10.1021/cr60292a002|journal=Chemical Reviews|volume=74|issue=6|pages=625–652|year=1974}}</ref> It was first isolated by [[Selman Waksman]] and his co-worker [[H. Boyd Woodruff]] in 1940.<ref>{{cite journal |author=Waksman S A |author2=Woodruff H B |title=Bacteriostatic and bacteriocidal substances produced by soil actinomycetes|journal=Proc Soc Exper Biol |volume=45 |pages=609–614 |year=1940}}</ref> It was approved by the U.S. [[Food and Drug Administration]] (FDA) on December 10, 1964 and launched by [[Merck Sharp and Dohme]] under the trade name Cosmegen.

== Research use ==
Because actinomycin can bind DNA duplexes, it can also interfere with [[DNA replication]], although other chemicals such as [[hydroxyurea]] are better suited for use in the laboratory as inhibitors of DNA synthesis.

Actinomycin D and its [[fluorescence|fluorescent]] derivative, [[7-aminoactinomycin D]] (7-AAD), are used as stains in [[microscopy]] and [[flow cytometry]] applications.  The affinity of these stains/compounds for GC-rich regions of DNA strands makes them excellent markers for DNA. 7-AAD binds to single stranded DNA; therefore it is a useful tool in determining apoptosis and distinguishing between dead cells and live ones.<ref>{{Cite journal | last1 = Toba | first1 = K. | last2 = Koike | first2 = T. | last3 = Watanabe | first3 = K. | last4 = Fuse | first4 = I. | last5 = Takahashi | first5 = M. | last6 = Hashimoto | first6 = S. | last7 = Takahashi | first7 = H. | last8 = Abe | first8 = T. | last9 = Yano | first9 = T. | last10 = Shibazaki | first10 = Y. | last11 = Itoh | first11 = H. | last12 = Aizawa | first12 = Y. | doi = 10.1034/j.1600-0609.2000.09005.x | title = Cell kinetic study of normal humanbone marrow hematopoiesis andacute leukemia using 7AAD/PY | journal = European Journal of Haematology | volume = 64 | issue = 1 | pages = 10–21 | year = 2000 | pmid =  10680701| pmc = }}</ref>

== References ==
{{reflist|32em}}

== External links ==
* {{MedlinePlusDrugInfo|medmaster|a682224}}

{{Chemotherapeutic agents}}

[[Category:Polypeptide antibiotics]]
[[Category:DNA replication inhibitors]]
[[Category:Depsipeptides]]
[[Category:Cyclic peptides]]
[[Category:IARC Group 3 carcinogens]]
[[Category:World Health Organization essential medicines]]
[[Category:RTT]]
[[Category:DNA intercalaters]]